NASDAQ:KMDA Kamada (KMDA) Stock Price, News & Analysis $5.94 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.87▼$6.1050-Day Range$4.78▼$6.2552-Week Range$4.08▼$6.53Volume26,823 shsAverage Volume25,117 shsMarket Capitalization$341.43 millionP/E Ratio25.83Dividend YieldN/APrice Target$14.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Kamada alerts: Email Address Kamada MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside144.1% Upside$14.50 Price TargetShort InterestHealthy0.14% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.36Based on 4 Articles This WeekInsider TradingN/AProj. Earnings Growth33.33%From $0.24 to $0.32 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.95 out of 5 starsMedical Sector216th out of 936 stocksPharmaceutical Preparations Industry91st out of 436 stocks 3.5 Analyst's Opinion Consensus RatingKamada has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKamada has only been the subject of 2 research reports in the past 90 days.Read more about Kamada's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.14% of the float of Kamada has been sold short.Short Interest Ratio / Days to CoverKamada has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kamada has recently increased by 63.81%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKamada does not currently pay a dividend.Dividend GrowthKamada does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KMDA. Previous Next 3.0 News and Social Media Coverage News SentimentKamada has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Kamada this week, compared to 1 article on an average week.Search Interest2 people have searched for KMDA on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Kamada to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kamada insiders have not sold or bought any company stock.Percentage Held by Insiders36.10% of the stock of Kamada is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.38% of the stock of Kamada is held by institutions.Read more about Kamada's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Kamada are expected to grow by 33.33% in the coming year, from $0.24 to $0.32 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kamada is 25.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Kamada is 25.83, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 164.48.Price to Book Value per Share RatioKamada has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Kamada's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Kamada Stock (NASDAQ:KMDA)Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Read More KMDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KMDA Stock News HeadlinesJuly 23 at 2:28 AM | lse.co.ukKamada Ltd Share Price (KMDA.US)July 21, 2024 | americanbankingnews.comKamada (NASDAQ:KMDA) Receives New Coverage from Analysts at StockNews.comJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 23, 2024 | finance.yahoo.comKMDA: Full Year Guidance Raised; Year-Over-Year Top-Line Growth of 23%…May 14, 2024 | stocknews.com3 Pharma Stocks With May PotentialMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kamada on Accelerated Trial Prospects and Strong Financial PerformanceMay 9, 2024 | finance.yahoo.comKamada Ltd. (NASDAQ:KMDA) Q1 2024 Earnings Call TranscriptMay 8, 2024 | investorplace.comKMDA Stock Earnings: Kamada Misses EPS, Misses Revenue for Q1 2024July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 8, 2024 | globenewswire.comKamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial GuidanceMay 8, 2024 | markets.businessinsider.comKamada earnings: here's what Wall Street expectsMay 1, 2024 | globenewswire.comKamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024April 19, 2024 | msn.comKamada Ekadashi 2024: When is Kamada Ekadashi? Know date, Ekadashi tithi, shubh muhurat, Parana time and significanceApril 19, 2024 | msn.comKamada Ekadashi 2024: Know significance, spiritual benefits, rituals and moreMarch 19, 2024 | finance.yahoo.comKMDA Aug 2024 10.000 callMarch 19, 2024 | finance.yahoo.comKMDA May 2024 5.000 callMarch 16, 2024 | finance.yahoo.comKMDA Apr 2024 10.000 callMarch 13, 2024 | finance.yahoo.comKMDA: Double Digit Growth Anticipated in 2024 with $158 Million in Expected Revenues and $28 Million in Expected Adjusted EBITDA…See More Headlines Receive KMDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KMDA CUSIPN/A CIK1567529 Webwww.kamada.com Phone(728) 940-6472Fax972-8940-6473Employees360Year FoundedN/APrice Target and Rating Average Stock Price Target$14.50 High Stock Price Target$18.00 Low Stock Price Target$11.00 Potential Upside/Downside+141.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.23 Trailing P/E Ratio26.09 Forward P/E Ratio25.00 P/E GrowthN/ANet Income$8.28 million Net Margins8.33% Pretax Margin8.47% Return on Equity5.50% Return on Assets3.69% Debt Debt-to-Equity RatioN/A Current Ratio4.24 Quick Ratio1.98 Sales & Book Value Annual Sales$142.52 million Price / Sales2.42 Cash Flow$0.44 per share Price / Cash Flow13.65 Book Value$4.25 per share Price / Book1.41Miscellaneous Outstanding Shares57,480,000Free Float36,730,000Market Cap$344.88 million OptionableOptionable Beta1.06 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Amir London (Age 55)Chief Executive Officer Comp: $611kMr. Chaime Orlev (Age 54)Chief Financial Officer Comp: $387kMr. Eran Nir (Age 51)Chief Operating Officer Comp: $332kMr. Jon R. Knight (Age 58)Vice President of US Commercial Operations Comp: $307kMr. Boris Gorelik (Age 43)Vice President of Business Development & Strategic Programs Comp: $410kMr. David Tsur (Age 74)Co-Founder & Independent Deputy Chairman of the Board Comp: $252kMr. Nir Livneh B.A. (Age 44)L.L.B., VP, General Counsel & Corporate Secretary Ms. Hanni Neheman (Age 54)Vice President of Marketing & Sales Ms. Liron Reshef (Age 52)Vice President of Human Resources Ms. Shavit BeladevVice President of Kamada PlasmaMore ExecutivesKey CompetitorsAltimmuneNASDAQ:ALTParatek PharmaceuticalsNASDAQ:PRTKFulcrum TherapeuticsNASDAQ:FULCBeyondSpringNASDAQ:BYSICTI BioPharmaNASDAQ:CTICView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 100,800 shares on 5/10/2024Ownership: 2.305%Acadian Asset Management LLCSold 73,603 shares on 5/10/2024Ownership: 0.767%View All Institutional Transactions KMDA Stock Analysis - Frequently Asked Questions How have KMDA shares performed this year? Kamada's stock was trading at $6.12 at the start of the year. Since then, KMDA stock has decreased by 2.9% and is now trading at $5.94. View the best growth stocks for 2024 here. How were Kamada's earnings last quarter? Kamada Ltd. (NASDAQ:KMDA) posted its earnings results on Wednesday, May, 8th. The biotechnology company reported $0.04 earnings per share for the quarter, missing analysts' consensus estimates of $0.06 by $0.02. The biotechnology company had revenue of $37.74 million for the quarter, compared to analysts' expectations of $38.01 million. Kamada had a trailing twelve-month return on equity of 5.50% and a net margin of 8.33%. How do I buy shares of Kamada? Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Kamada own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kamada investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN) and NIC (EGOV). This page (NASDAQ:KMDA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kamada With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
